Patents by Inventor Leonard Buckbinder

Leonard Buckbinder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12115178
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: October 15, 2024
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • Patent number: 11813272
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 14, 2023
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • Publication number: 20230331705
    Abstract: The present disclosure relates to compounds of formulae (I)-(VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Application
    Filed: May 19, 2021
    Publication date: October 19, 2023
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • Publication number: 20230234967
    Abstract: The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.
    Type: Application
    Filed: May 27, 2021
    Publication date: July 27, 2023
    Inventors: Alessandra Bartolozzi, John Robert Proudfoot, Timothy Briggs, John Mancuso, Maxence Bos, Tianlin Guo, Vu Linh Ly, Anna Blois, Bernard Lanter, Steven John Taylor, Leonard Buckbinder
  • Patent number: 11058698
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: July 13, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • Patent number: 10953027
    Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 23, 2021
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, John Robert Proudfoot, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Afrand Kamali Sarvestani, Leonard Buckbinder, Bernard Lanter, Ferdinand Edward Massari, Koji Yasuda, Spencer Cory Peck, Cheri Snedeker, Diana Le, Jessica Alexander, Anna Liang, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr.
  • Publication number: 20090118316
    Abstract: The present invention relates to methods of stimulating osteoblast function with a PYK2 inhibitor in subjects with osteoporosis, bone fractures, non-unions, pseudoarthroses, periodontal disease or other disorders of bone metabolism. Optionally, the method further comprises administration of a second therapeutic bone agent. The present invention also relates to methods to identify a PYK2 inhibitor effective as a therapeutic bone agent comprising administering a test agent to an osteoblast-like cell and determining if osteoblast function is stimulated. Optionally, the identifying method further comprises contacting the test agent with PYK2 and determining if PYK2 activity is inhibited.
    Type: Application
    Filed: June 10, 2005
    Publication date: May 7, 2009
    Inventors: Lisa M. Olson, Thomas A. Brown, Leonard Buckbinder, Angel Guzman-Perez, John C. Kath, Hua Zhu Ke, Michael J. Luzzio
  • Publication number: 20040241755
    Abstract: This invention relates to human chondrocyte activity (growth)/differentiation/production of extracellular matrix) and to the effect of Sox9 transcription factor and Col2 enhancer as a measure for such activity. It also relates to a chimeric cell and assay utilizing such cell useful in predicting the effect of sample compounds on chondrocyte activity as measured by Sox9 and Col2 expression/activity.
    Type: Application
    Filed: June 2, 2003
    Publication date: December 2, 2004
    Applicant: Pfizer Inc.
    Inventors: Leonard Buckbinder, Jean F. Schaefer
  • Publication number: 20030224349
    Abstract: This invention relates to in vitro screening and assay methods for the selection of anti-inflammatory compounds that exhibit minimized effects on the differentiation of human osteoblasts.
    Type: Application
    Filed: June 2, 2003
    Publication date: December 4, 2003
    Applicant: Pfizer Inc.
    Inventor: Leonard Buckbinder
  • Publication number: 20030166899
    Abstract: The present invention relates to members of the family of proteins known as ADAMTS proteins, the new members being designated ADAMTS-E polypeptides. The invention also relates to polynucleotides encoding ADAMTS-E, antibodies to ADAMTS-E, assays for studying the function of ADAMTS-E, assays for determining stimulators or inhibitors of ADAMTS-E, and to the use of ADAMTS-E polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.
    Type: Application
    Filed: April 26, 2001
    Publication date: September 4, 2003
    Inventors: Leonard Buckbinder, Peter Geoffrey Mitchell, Roderick Thomas Walsh, Timothy Scott Wachtmann
  • Publication number: 20020090373
    Abstract: The present invention relates to a member of the family of proteins known as ADAMTS proteins, the new member being designated ADAMTS-SI. The invention also relates to polynucleotides encoding ADAMTS-SI, antibodies to ADAMTS-SI, assays for studying the function of ADAMTS-SI, assays for determining agonists or antagonists of ADAMTS-SI, and to the use of ADAMTS-SI polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.
    Type: Application
    Filed: October 5, 2001
    Publication date: July 11, 2002
    Inventors: Leonard Buckbinder, Peter G. Mitchell, Jean F. Schaefer, Roddy T. Walsh
  • Publication number: 20010049106
    Abstract: The present invention relates to a member of the family of proteins known as ADAMTS proteins, the new member being designated ADAMTS-M. The invention also relates to polynucleotides encoding ADAMTS-M, antibodies to ADAMTS-M, assays for studying the function of ADAMTS-M, assays for determining agonists or antagonists of ADAMTS-M, and to the use of ADAMTS-M polypeptides or polynucleotides in diagnostic, biotherapeutic, or gene therapy methods.
    Type: Application
    Filed: April 17, 2001
    Publication date: December 6, 2001
    Inventors: Leonard Buckbinder, Peter G. Mitchell, Timothy S. Wachtmann, Roderick T. Walsh
  • Patent number: 5886149
    Abstract: This present invention concerns polypeptide molecules comprising human p53 response protein PIGI-1.
    Type: Grant
    Filed: November 20, 1996
    Date of Patent: March 23, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Leonard Buckbinder, Randy Talbott, Bernd R. Seizinger, Nikolai Kley
  • Patent number: 5667987
    Abstract: Nucleic acid sequences, particularly DNA sequences, coding for all or part of p53 response protein PIGI-1, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials are disclosed. The invention also concerns polypeptide molecules comprising all or part of p53 response protein PIGI-1, and methods for producing these polypeptide molecules.
    Type: Grant
    Filed: July 12, 1994
    Date of Patent: September 16, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leonard Buckbinder, Randy Talbott, Bernd R. Seizinger, Nikolai Kley